WO2007029676A1 - Feuille de tissu biologique et procédé de préparation - Google Patents

Feuille de tissu biologique et procédé de préparation Download PDF

Info

Publication number
WO2007029676A1
WO2007029676A1 PCT/JP2006/317510 JP2006317510W WO2007029676A1 WO 2007029676 A1 WO2007029676 A1 WO 2007029676A1 JP 2006317510 W JP2006317510 W JP 2006317510W WO 2007029676 A1 WO2007029676 A1 WO 2007029676A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
amniotic membrane
cell
sheet
derived
Prior art date
Application number
PCT/JP2006/317510
Other languages
English (en)
Japanese (ja)
Inventor
Kouji Hashimoto
Yuuji Shirakata
Junji Hamuro
Wakana Ito
Original Assignee
Arblast Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arblast Co., Ltd. filed Critical Arblast Co., Ltd.
Publication of WO2007029676A1 publication Critical patent/WO2007029676A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells

Definitions

  • the present invention relates to a biological tissue sheet.
  • the present invention relates to a biological tissue sheet containing cells derived from keratoconjunctival epithelial cells, skin epidermal cells, hair follicle epithelial cells, oral mucosal epithelial cells, airway mucosal epithelial cells, intestinal mucosal epithelial cells, and the like. It relates to the production method of the sheet and the use (transplantation method etc.) of the sheet.
  • the skin is an organ that covers the outermost layer of a living body, and is a kind of barrier that protects a living body from an external force.
  • the skin is composed of the epidermis, dermis, and subcutaneous tissue.
  • the epidermis is mainly keratinocyte power, which contains a small number of pigment cells, Langerno cells, and cells.
  • the cells that make up the epidermis are mainly keratinocytes, (1) keratinocytes that have lost their nuclei, which occupy the outermost layer, (2) cells that have nuclei beneath them (granular cells, spiny cells, basal cells)
  • the epidermis basement membrane exists between the basal cells in the lowermost layer and the dermis.
  • the basal layer is a single cell layer, which is the mother cell layer of epidermal keratinocytes, and it is thought that the only cells with the ability to divide are basal cells.
  • a state in which the epidermis has been lost for some reason is an ulcer.
  • the epidermis is regenerated and the ulcer surface becomes epithelialized by the proliferation of keratinocytes from the periphery or by the proliferation of keratinocytes derived from some hair follicles.
  • epithelialization takes time only by regeneration of the epidermis from the surrounding area.
  • the cell cycle of the basal layer is about 450 hours.
  • Daughter cells born by division change morphologically and functionally as they move to the spinous layer, and then keratinize through the granular layer to become the stratum corneum and eventually fall out of the body.
  • the time until dropout is called turnover time, which is estimated to be 47 to 48 days.
  • epidermal keratinocytes are divided into stem cells, transit-amplifying cells, post-mitotic cells based on their ability to divide. It is classified into three types of cells (post-dividing cells).
  • a stem cell is a cell that has infinite self-renewal ability and generates a transit-amplifying cell by division.
  • Transit-amplifying cells have a certain division ability and become transit-amplifying cells after division, but eventually lose division ability and become post-mitotic cells.
  • Stem cell of epidermis is considered to have the following characteristics.
  • epidermal growth factor (EGF) family Eko EGF
  • EGF transforming growth factor
  • TGF-a heparin binding EGF like growth factor
  • HB—EGF betacellulin
  • amphiregulin amphiregulin
  • neuregulins neuregulins
  • TGF— ⁇ TGF- ⁇
  • HB—EGF heparin binding EGF like growth factor
  • amphiregulin amphiregulin
  • neuregulins heparin binding EGF like growth factor
  • other forces that are actually involved in epidermal keratinocyte proliferation TGF— ⁇ , HB—EGF, and amphiregulin. It is thought to be regrin, and these factors have been shown to act autoproliferatively on epidermal keratinocytes.
  • TGF- ⁇ , vitamin D, retinoic acid, etc. are known as factors that suppress the growth of epidermal keratinocytes.
  • JP-A-10-277143 JP-A-10-277143 (Patent Document 1) describes a graft for treating a full-thickness defect such as human skin and a method for producing the same.
  • the graft disclosed in this document is made by embedding fibroblasts derived from dermal tissue in human fibrin sheet and attaching the epidermal tissue to the surface of this sheet.
  • the epidermis sheet is divided into an autologous cultured epidermis sheet and an autologous cultured epidermis sheet depending on the origin of the cells used.
  • autologous skin sheet transplantation is mainly intended to cover and engraft the epidermal defect site, while transplantation of other culture skin sheet is effective as a biological dressing.
  • epidermal keratinocytes produce various cell growth factors and cytokines, and the effectiveness of other-cultured epidermal sheets has been revealed.
  • Cornea One of the tissues expected to contribute to regenerative medicine alongside the skin is the cornea. Cornea
  • the keratoconjunctival epithelial cells are always in contact with the outside world, and have a protective action to protect the eyeball with foreign substances such as microorganisms in the outside world and light rays such as ultraviolet rays. That is, keratoconjunctival epithelial cells are transparent to the cornea It plays a vital role in protecting the sex and the entire eyeball and maintaining homeostasis.
  • the cornea may become turbid and lose its transparency due to pathological conditions such as keratitis, corneal ulcer, and perforation.
  • pathological conditions such as keratitis, corneal ulcer, and perforation.
  • treatment by cornea transplantation using the cornea provided by the eyeball donor Kas et al. Has been performed.
  • the transparent cornea is transplanted after removing the cornea from which the transparency of the patient has been lost, and the transparency is restored by this transplantation, and visual acuity can be restored again.
  • corneal transplantation can be expected to have an effective therapeutic effect
  • epilepsy diseases that cannot be addressed by corneal transplantation alone. Examples include Stevens-Johnson syndrome, pemphigoid, chemical trauma, and burns. Normally, keratoconjunctival epithelial cells repeat division every day, old cells peel off, and new cells are regenerated from stem cell tissue. However, it has been found that in the above pathological conditions, the stem cell tissue that regenerates the cornea is damaged.
  • Stem cell tissue that regenerates corneal epithelium is called “corneal limbal tissue”, and is limited to the boundary between black eyes and white eyes, and is in a special environment exposed to the outside world.
  • this stem cell tissue itself is eradicated by some kind of disorder.
  • the defective part is covered with surrounding conjunctival epithelium, lacking transparency, and exerting an extremely low visual acuity.
  • the corneal limbus is withered, so that the transplanted cornea cannot be maintained for a long time simply by transplanting the cornea.
  • an amniotic membrane transplantation method As one method for transplanting the limbus, an amniotic membrane transplantation method has been developed (Medical Asahi, September 1999 issue: p62-65, N Engl J Med340: 1697-1703, 1999: Non-patent document 1 ).
  • the amniotic membrane used in this transplantation method is obtained from the placenta of pregnant women who have undergone cesarean section. Since the amniotic membrane has a thick basement membrane, it acts as a substrate for the proliferation and differentiation of keratoconjunctival epithelial cells when transplanted.
  • amniotic membrane since the amniotic membrane has both anti-inflammatory and scarring suppression effects that are almost immunogenic, the keratoconjunctival epithelium and these stem cell tissues transplanted onto the amniotic membrane are rejected by the transplant recipient (recipient). Etc. will be protected.
  • Patent Document 1 Japanese Patent Laid-Open No. 10-277143
  • Non-Patent Document 1 Medical Asahi, September 1999 issue: p62-65, N Engl J Med340: 1697-1703, 1999
  • transplantation using the graft is regarded as xenotransplantation or equivalent, and is considered to have a serious problem in ethics and safety. In fact, there are no examples of xenotransplantation being put to practical use in the medical field!
  • Transplantation of cultured epidermis sheets made it possible to cover a wide range of wound surfaces by subculturing keratinocytes from stamp-sized skin. In addition, since it can be stored frozen, it can be applied to the treatment of intractable and recurrent skin ulcers that require repeated transplantation. It is not always easy to satisfactorily engraft culture sheets produced by conventional culture methods, for example, transplanted cultured skin sheets. This is because the cultured epidermis sheet lacks the components of the basement membrane and the stratified epidermis does not form a strong stratum corneum.
  • the 3D cultured skin developed by Bell is also the closest to the skin at present, with both the stratum corneum and the granule layer being recognized, but due to the complexity of the procedure and the need for special techniques, it is still in Japan. Not popular . Three-dimensional cultured skin has already been demonstrated overseas and has already been commercialized. However, it is not possible to expect permanent engraftment with the ability to promote epithelialization in allogeneic transplantation. In Japan, there is little prospect of widespread transplantation in terms of ethics and safety, and there has been a focus on improving autotransplantation.
  • the present invention has been made in view of the above background and problems, and an object thereof is to provide a biological tissue sheet that is expected to have a high therapeutic effect and has high safety at the time of transplantation.
  • the present inventors first tried to produce a cultured skin sheet. Specifically, in consideration of safety, the condition that the cells derived from different animals (feeder cells) are not used when culturing epidermal keratinocytes is used, and good growth and tissue formation of epidermal keratinocytes are achieved.
  • feeder cells the condition that the cells derived from different animals
  • the fibroblasts interact with collagen in the amniotic membrane to ensure good growth of the fibroblasts themselves, and the nutritional components necessary for the survival, proliferation and organization of epidermal keratinocytes It was speculated that a state of being supplied from fibroblasts was created through this, and as a result, a high-quality epidermal cell layer could be constructed.
  • the present inventors have succeeded in producing a safe and practical biological tissue sheet that does not use cells derived from different animals.
  • the present invention has been completed on the basis of the above results and knowledge, and provides the following configuration.
  • the present invention provides a biological tissue sheet containing biological cells grown on a collagen sheet placed on human fibroblasts. It is preferable to use amniotic membrane as the collagen sheet here.
  • Amniotic membrane is not only immunogenic but also has anti-inflammation and anti-scarring effects.
  • As the collagen sheet it is particularly preferable to use amniotic membrane from which the epithelium (epithelial cell layer) has been removed. This is because the absence of epithelium improves the growth of living cells seeded thereon. This is also because a further reduction in immunogenicity is achieved.
  • amniotic membrane added with trehalose is used as a collagen sheet. Such amniotic membrane is excellent in flexibility and functions better as a substrate for cell culture.
  • a medium for growing cells derived from living organisms (1) a serum-free medium, or (2) a medium containing only serum derived from the recipient as a serum component can be used.
  • the biological cell is preferably a cell derived from the corneal epithelium, conjunctival epithelium, skin epidermis, hair follicle epithelium, oral mucosa, airway mucosa or intestinal mucosa.
  • a biological tissue sheet according to another embodiment of the present invention includes a layered cell layer formed by expanded cells.
  • the biological tissue sheet of the present invention is, for example, directly or amniotic (amniotic membrane different from the collagen sheet used as a culture substrate.
  • amniotic membrane different from the collagen sheet used as a culture substrate in one embodiment of the present invention
  • the “second amniotic membrane is used for convenience. And also transplanted into a tissue defect. In the latter case, typically, after transplanting the second amniotic membrane to the tissue defect, a biological tissue sheet is transplanted on the amniotic membrane.
  • the present invention further provides a method for producing a biological tissue sheet.
  • the production method of the present invention includes the following steps. That is, (a) preparing human fibroblasts; (b) placing a collagen sheet on the human fibroblasts seeded in a culture vessel; (c) preparing living-derived cells; Inoculating a biological cell on the collagen sheet; and (d) culturing and proliferating the biological cell in the absence of a heterologous animal cell.
  • step (b) A collagen sheet is placed after a predetermined time has elapsed since the seeding of human fibroblasts. This step promotes the adhesion and monolayering of human fibroblasts to the culture container, thereby achieving a high quality sheet of the biological tissue sheet.
  • step (b) ′ is a step of culturing the human fibroblast for a predetermined time.
  • step the infiltration of human fibroblasts into the collagen sheet is promoted, and the high quality of the living yarn and woven sheet can be achieved.
  • the step of bringing the outermost layer into contact with air is further performed. This step promotes keratinization (epithelialization) of the cell layer.
  • amniotic membrane is used as the collagen sheet in step (b). It is particularly preferable to use amniotic membrane from which the epithelium (epithelial cell layer) has been removed as the collagen sheet. . On the other hand, in one embodiment of the present invention, amniotic membrane added with trehalose is used as a collagen sheet.
  • a serum-free medium or (2) a medium containing only serum derived from a recipient as a serum component can be used.
  • the biological cell is preferably a cell derived from the corneal epithelium, conjunctival epithelium, skin epidermis, hair follicle epithelium, oral mucosa, airway mucosa or intestinal mucosa.
  • FIG. 1 is a flowchart showing an amnion epithelial removal procedure.
  • FIG. 2 is a diagram for explaining an amniotic membrane fixing method.
  • the amniotic membrane is sandwiched between a pair of frames, and in (b), the amniotic membrane is sandwiched between the frame and a flat plate member.
  • FIG. 3 is a HE-stained image showing the state of the cultured skin sheet on day 17 after transplantation.
  • FIG. 4 is a diagram showing the results of immunohistochemical staining for cultured skin sheets.
  • FIG. 5 shows the results of immunohistochemical staining of cultured skin sheets.
  • FIG. 6 Experimental method (upper) and experimental results (lower) regarding the relationship between the seeding time of epidermal keratinocytes and the quality of the cultured skin sheet to be constructed.
  • the lower left is the HE-stained image of the cultured skin sheet constructed under condition 1 (time after amnion placement, time to seed the epidermis keratinocytes), the lower right is condition 2 (after amnion placement, It is an HE-stained image of a cultured skin sheet constructed under the condition of seeding epidermal keratinocytes without taking time.
  • FIG. 7 Experimental method (upper) and experimental result (lower) regarding the relationship between the time of placing (attaching) the amniotic membrane and the quality of the cultured skin sheet to be constructed.
  • the lower left is an HE-stained image of a cultured skin sheet constructed under Condition 1 (conditions where the fibroblast seeding power is short in the time interval until placement on the amniotic membrane), and the lower right is Condition 2 (fibroblast seeding power is up to the amnion placement)
  • Condition 1 condition where the fibroblast seeding power is short in the time interval until placement on the amniotic membrane
  • Condition 2 fibroblast seeding power is up to the amnion placement
  • FIG. 8 is an HE-stained image of a cultured corneal epithelial sheet constructed using amniotic membrane and human fibroblasts.
  • FIG. 9 is an immunostained image (confocal laser microscope, 100 ⁇ magnification) of a cultured corneal epithelial sheet constructed using amniotic membrane and human fibroblasts.
  • Upper row (A) shows immunostaining results for keratin 3.
  • the lower panel (B) shows the result of immunostaining for keratin 12.
  • Left side Green color Display primary After staining with antibody, stained with secondary antibody Al eX a488.
  • Center Red coloration Colored with DNA staining reagent PI.
  • the present invention provides a biological tissue sheet having the following constitution. That is, it is a living tissue sheet containing living body-derived cells grown on a collagen sheet placed on human fibroblasts. Living body-derived cells form a cell layer.
  • the features of the biological tissue sheet of the present invention and its production method will be described in detail below.
  • the biological tissue sheet of the present invention comprises (a) a step of preparing human fibroblasts, (b) a step of placing a collagen sheet on the human fibroblasts seeded in a culture vessel, (c) Preparing a cell derived from a living body and seeding the living body-derived cell on the collagen sheet; and (d) culturing and proliferating the living body-derived cell in the absence of a heterologous animal cell. Can do.
  • each step will be described.
  • human fibroblasts are prepared.
  • the origin of human fibroblasts is not particularly limited.
  • human fibroblasts derived from skin tissue, ocular tissue (cornea, sclera, conjunctiva, etc.), or oral mucosal tissue can be used.
  • human fibroblasts provided in the form of cell lines can be used, it is preferable to use recipient-derived fibroblasts from the viewpoint of biocompatibility.
  • human fibroblasts may be selected in consideration of the type of cells derived from a living body to be cultured on a collagen sheet (in other words, the type of living tissue sheet to be produced).
  • human fibroblasts derived from the same tissue as the living body cell to be used may be employed.
  • biologically derived cells and human fibroblasts the proliferation of the biologically derived cells and the expected tissue properties are improved.
  • An example of a preferred combination of biological cells and human fibroblasts is a combination of epidermal keratinocytes (biological cells) and human fibroblasts derived from skin tissue. Can be mentioned.
  • Human fibroblasts can be cultured by a conventional method.
  • human fibroblasts can be cultured in an appropriate medium in the presence of 37 ° C and 5% CO. Used for human fibroblast culture
  • the medium to be used is not particularly limited as long as the cells can grow, and a medium usually used for fibroblast culture may be used.
  • a DMEM medium containing serum such as fetal calf serum
  • serum added to the medium human serum, fetal bovine serum, sheep serum, and the like can be used.
  • serum it is preferable to use a serum that is derived from the same species (human serum) and autologous serum (that is, the serum of the recipient itself).
  • autologous serum that eliminates the risk of causing immune rejection.
  • Human fibroblasts may be cultured using a medium supplemented with growth factors and antibiotics. By using growth factors and antibiotics, cell proliferation rate and survival rate can be improved and contamination can be prevented.
  • Human fibroblasts may be cultured using a medium that is serum-free and does not contain proteins derived from different animals. That is, a serum-free culture method may be employed as the culture method in the present invention. In such an embodiment, problems such as immune rejection due to contamination of serum-derived components can be avoided.
  • step (b) first, the prepared human fibroblasts are seeded in a culture vessel.
  • a culture container of an appropriate size.
  • a commercially available culture insert or petri dish with a moderate force can be selected and used.
  • the material of the culture vessel and the presence or absence of surface coating are not particularly limited.
  • Human fibroblasts for example, plated at a cell density of 10,000 to 50,000 pieces / cm 2. If the cell density at the time of seeding is too small, one of the effects of the present invention that the growth of living cells is improved by using human fibroblasts is not sufficiently exhibited. On the other hand, sowing If the cell density at the time is too high, the nutrients supplied to the culture solution are insufficient, which is not preferable.
  • a collagen sheet is placed on the human fibroblasts seeded in the culture vessel.
  • the collagen sheet is placed after a predetermined time has passed for the seeding force of human fibroblasts. Ensuring sufficient time after seeding of human fibroblasts promotes adhesion and monolayering of human fibroblasts to the culture container, and is effective in producing high-quality biological tissue sheets.
  • the predetermined time here is, for example, 1 hour or more, preferably 2 hours or more, more preferably 4 hours or more, and even more preferably 1 day or more (eg, 1 day, 2 days, 3 days). is there.
  • the "collagen sheet” functions as a culture substrate for living cells.
  • the type of collagen used as a raw material for the collagen sheet is not particularly limited, and type I collagen, type III collagen, type IV collagen and the like can be used. A mixture of a plurality of types of collagen can also be used. These collagens can be extracted and purified from the skins of animals such as pigs, sushi, and hedges, and connective tissues such as soft bones by acid solubilization, alkali solubilization, enzyme solubilization, etc. it can. For the purpose of reducing antigenicity, it is preferable to use a so-called atherocollagen in which the telopeptide is removed by treatment with a degrading enzyme such as pepsin or trypsin. Collagen derived from amnion, particularly human amnion, may be used as a material for the collagen sheet.
  • the term “derived from amniotic membrane” means that it is widely obtained using amnion as a starting material.
  • amniotic membrane is a membrane that covers the outermost layer of the uterus and placenta in mammals, and is composed of a basement membrane and an epithelial layer formed on a collagen-rich parenchyma.
  • Amniotic membranes such as humans, monkeys, chimpanzees, pigs, horses, and ushi can be used. Among them, it is preferable to use human amniotic membrane. It also has advantages in terms of safety, including immunogenicity and virus infection. For example, human amnion can also collect force such as human fetal membrane and placenta obtained as a postpartum at delivery.
  • human amniotic membrane can be prepared by treating and purifying an integral body consisting of human fetal membrane, placenta and umbilical cord obtained immediately after delivery.
  • a treatment and purification method a known method such as a method described in JP-A-5-56987 can be adopted. That is, the amniotic membrane is peeled off from the fetal membrane obtained at the time of delivery Then, the remaining tissue is removed by physical treatment such as ultrasonic washing and enzyme treatment, and human amniotic membrane can be prepared through a washing step as appropriate.
  • the human amniotic membrane thus prepared can be stored frozen until use. Freezing of the human amniotic membrane can be performed, for example, at ⁇ 80 ° C. in a liquid in which DMEM (Dulbecco's modified Eagle's medium) and glycerol are mixed in an equal volume ratio. Cryopreservation is expected to improve operability as well as decrease antigenicity.
  • amniotic membrane can be used as it is, it is preferable to use a material obtained by removing the epithelium from the amniotic membrane by reptile treatment or the like.
  • a material obtained by removing the epithelium from the amniotic membrane by reptile treatment or the like When using human amniotic membrane from which the epithelium has been removed, it is preferable to seed biologically-derived cells on the surface side (ie, the basement membrane side) where the epithelium has been removed in step (c) described later. This is because this surface side is rich in type IV collagen, and it is considered that the seeded living cells are proliferated and stratified well.
  • a step of preparing an amniotic membrane separated from a living body (1) A step of preparing an amniotic membrane separated from a living body.
  • the epithelial removal method it is possible to completely remove the epithelium while suppressing damage to the basement membrane as much as the conventional manual epithelial removal method. That is, according to the epithelial removal method, an amniotic membrane having a basement membrane in which the epithelium is completely removed and the original structure is well maintained can be obtained. Such an amniotic membrane functions well as, for example, a cell culture substrate (base material).
  • the following epithelial removal method is very easy to operate and requires less operation time than conventional manual methods. It is also easy to process a large number of amniotic membranes at the same time. Furthermore, since skilled technology is not particularly required, it is easy to automate.
  • each step of the epithelial removal method will be described in detail (see FIG. 1).
  • step (1) prepare the amniotic membrane.
  • the amniotic membrane here is preferably human amniotic membrane.
  • human amnion can be collected by force such as human fetal membrane or placenta obtained as a postpartum at the time of delivery.
  • the human amniotic membrane can be prepared by treating and purifying an integral product such as human fetal membrane, placenta and umbilical cord obtained immediately after delivery.
  • known methods such as the method described in JP-A-5-56987 can be employed. Typically, this step is performed as follows.
  • a part of the placenta tissue is collected at the time of delivery, and then the amniotic tissue is manually detached from the placenta tissue. You may freeze once at this stage.
  • amniotic membrane from which blood cell components and chorion are removed at this stage, but after the freeze-thaw treatment (step 2) described later, removal of blood cell components and peeling of Z or chorion are performed. You can also.
  • the human amniotic membrane thus prepared can be stored frozen until the next treatment. Freezing of the human amniotic membrane can be performed, for example, at ⁇ 80 ° C. in a solution in which DMEM (Dulbecco's modified Eagle's medium) and glycerol are mixed in an equal volume ratio. Cryopreservation is expected to improve operability as well as decrease antigenicity.
  • DMEM Dulbecco's modified Eagle's medium
  • glycerol glycerol
  • amniotic membrane prepared by the above procedure is fixed to a frame and then subjected to the subsequent treatment. It becomes easy to handle by fixing the amniotic membrane with a frame.
  • FIG. 2 shows a specific example of how to fix the amniotic membrane.
  • two frames (1, 2) of the same shape are used.
  • the amniotic membrane 10 is fixed by holding the edges of these two frames. Fix the amniotic membrane in an expanded state.
  • the amniotic membrane 10 is fixed using the frame 3 and the plate-like member 4.
  • the amniotic membrane 10 is spread on the plate-like member 4.
  • the epithelial side of the amniotic membrane 10 is turned up.
  • the upper force of the amniotic membrane 10 is also put on the frame 3, and the edge of the amniotic membrane 10 is sandwiched between the plate-like member 4 and the frame 3.
  • the trypsin solution can be brought into contact only with the epithelial side of the amniotic membrane (for example, a trypsin solution is added inside the frame 3).
  • trypsin treatment can be performed without affecting the parts other than the epithelium (the amnion dense layer and the basement membrane). In other words, while the trypsin acts on the epithelium of the amniotic membrane, it is possible to protect the denseness of the amniotic membrane, etc.
  • the amniotic membrane is once frozen and then thawed.
  • This freezing and thawing process makes it easier for the amniotic epithelial layer to peel off during subsequent trypsin treatment. This is thought to be due to the loosening of the adhesive state (bonded state) between the amniotic epithelial layer and the basement membrane.
  • a freezing temperature of about 20 ° C to about 80 ° C can be used. In consideration of the fact that a sufficient frozen state can be obtained and a general-purpose freezer can be used, it is preferable to freeze at about 80 ° C.
  • a melting temperature of about 4 ° C to about 50 ° C can be employed. Preferably the melting temperature is about 37 ° C.
  • freeze-thaw treatment it is preferable to repeat the freeze-thaw treatment.
  • the effect of the freeze-thaw treatment that the epithelium is easily detached in the subsequent trypsin treatment is enhanced.
  • the freeze-thaw treatment is preferably performed twice under the conditions of a freezing temperature of -80 ° C and a thawing temperature of 37 ° C.
  • the conditions (freezing temperature and thawing temperature) for each time when the freeze-thaw treatment is repeatedly performed may be the same, partly different, or different from each other. However, from the viewpoint of operability, it is preferable that the conditions are the same each time.
  • the amniotic membrane after the freeze-thaw treatment is treated with trypsin.
  • Trypsinization is performed by bringing a trypsin solution into contact with the amniotic membrane.
  • a trypsin solution with a trypsin concentration of about 0.01% (w / v) to about 0.05% (w / v).
  • a trypsin solution having a trypsin concentration of about 0.02% (w / v) is used. If the trypsin concentration of the trypsin solution is too low, the action of trypsin will not be fully exerted. On the other hand, if the trypsin concentration is too high, trypsin can act well on the amniotic epithelium, while trypsin also acts on the amnion dense layer and the basement membrane, which may damage the part.
  • trypsins are commercially available such as those derived from ushi, porcine, and human.
  • Trypsin-EDTA Invitrogen
  • trypsin 1: 250 Sigma
  • a chelating agent is usually added to the trypsin solution, but the chelating agent is not essential.
  • EDTA As a chelating agent, EDTA, NTA, DTPA, HEDTA, GLDA, etc. can be used. Any combination of these may be used.
  • the chelating agent is added, for example, to a concentration of about O.lmM to about 0.6 mM.
  • trypsin treatment under conditions where only the amnion epithelial side is in contact with the trypsin solution. This is to protect the action force of trypsin on parts other than the amniotic epithelium. For example, immerse only the amnion epithelium side in a trypsin solution, do not add trypsin solution to the amnion epithelium side, apply it, and block the amnion chorion side to avoid contact with the solution. Thereafter, only the amnion epithelial side can be brought into contact with the trypsin solution by, for example, immersing it completely in a trypsin solution.
  • the amniotic membrane (frame-fixed amniotic membrane) fixed in advance to the frame as shown in Fig. 2b is used, only the epithelial side of the amniotic membrane is exposed, so the frame-fixed amniotic membrane is immersed in a trypsin solution, for example. It is possible to contact only the amnion epithelium side with the trypsin solution.
  • This method also has the advantage that the trypsin treatment can be performed by a simple operation of immersing the frame-fixed amniotic membrane.
  • the trypsin treatment time (contact time of the trypsin solution) is, for example, about 5 minutes to about 60 minutes. Good It is preferably about 10 minutes to about 20 minutes, more preferably about 15 minutes. If the treatment time is too short, trypsin cannot be sufficiently exerted, resulting in insufficient removal of the amniotic epithelium. On the other hand, if the treatment time is too long, trypsin may also act on the basement membrane and dense layer of the amniotic membrane to damage the part.
  • the temperature condition of the trypsin treatment is, for example, about 25 ° C. to about 42 ° C. so that trypsin works well.
  • the trypsin treatment can be performed in a plurality of times.
  • the amniotic membrane is washed. This washing removes the attached trypsin solution and simultaneously removes the amniotic epithelium (epithelial cells). For example, leave it in a liquid with an appropriate flow (for example, flowing water), shake it in a suitable liquid (for example, shake up and down), or apply ultrasonic waves while immersed in a suitable liquid.
  • the amniotic membrane after trypsinization is washed by adding.
  • the liquid used for washing include physiological saline, phosphate buffer, pure water, and DMEM.
  • the washed amniotic membrane may be refrigerated or frozen until use.
  • it can be stored in a state of being immersed in a storage solution containing glyceride (for example, 50% glycerol-containing DMEM (Dulbecco'S Modofied Eagle Medium: GIBCOBRL)).
  • glyceride for example, 50% glycerol-containing DMEM (Dulbecco'S Modofied Eagle Medium: GIBCOBRL)
  • amniotic membrane to which trehalose is added can also be used. In this case, it is preferable that the epithelium of the amniotic membrane is removed.
  • trehalose increases the flexibility of the amniotic membrane, particularly when it is lyophilized (see Japanese Patent Application 2005-214339 for details). Amniotic membrane with trehalose works well as a substrate for cell culture (see Japanese Patent Application No. 2005-214339 for details).
  • the matrix protein inside the amniotic membrane is weakened, the strength of the amniotic membrane is reduced and it becomes susceptible to damage. Also, moisture cannot be firmly held inside, and it becomes brittle and loses elasticity.
  • G Rehalose acts on loosened bonds in matrix proteins to strengthen the bonds between the proteins, thereby normalizing the water retention function inside the amniotic membrane, maintaining the original moisture, cohesion, and elasticity of the amniotic membrane. Expected. By adding trehalose, it is considered that the matrix protein inside the amniotic membrane becomes soft with freezing and drying treatment, and in particular, it can effectively prevent swelling and weakening in water.
  • Trenorose (substance name, generic name) is a compound represented by (X-D-Glucopyranosyl (1,1) —a—D—Glucopyranosi de.
  • Attachment of trehalose to the amniotic membrane can be performed, for example, by treating the amniotic membrane with a trehalose solution.
  • the amniotic membrane is immersed in a solution obtained by dissolving trehalose in distilled water or phosphate buffered saline (PBS (-)) so that the concentration is 5% (w / v) to 20% (w / v). To do.
  • the temperature during immersion is, for example, in the range of 4 ° C to 37 ° C.
  • the immersion time is, for example, in the range of 1 hour to 1 day.
  • Treha for example, Treha (registered trademark) provided by Hayashibara Shoji Co., Ltd. or HI Plus Plus Life Science Co., Ltd. can be used.
  • a method of adding trehalose to the amniotic membrane As a method of adding trehalose to the amniotic membrane, a method of applying a trehalose solution to the surface of the amniotic membrane, a method of spraying the trehalose solution to the surface of the amniotic membrane, a method of adding trehalose directly to the surface of the amniotic membrane, etc. may be adopted.
  • a reconstructed amniotic membrane can also be used as the collagen sheet.
  • amniotic membrane that has been once decomposed by homogenizer, ultrasonic wave, or enzymatic treatment and reconstructed into a membrane shape can be used.
  • the treatment method is preferably a homogenizer. This is because it is expected to keep the minute structure of the basement membrane relatively high.
  • the conditions (rotation speed) of the homogenization treatment are, for example, 3000 rpm to 50000 rpm, preferably 10000 rpm to 40000 rpm, and more preferably ⁇ 30000 rpm.
  • an amnion in which the chorionic side of the amniotic membrane is coated with a bioabsorbable material can also be used as the collagen sheet.
  • a bioabsorbable material used for such purposes it is earlier than amniotic membrane.
  • Decomposition 'It is preferable to adopt a material that is absorbed.
  • polydaractin 910, gelatin, collagen, polylactic acid and the like can be suitably used as the bioabsorbable material here.
  • the form of the bioabsorbable material used for reinforcement is not particularly limited.
  • the amniotic membrane is reinforced by covering the amnion chorion side with a bioabsorbable material formed into a mesh or sheet.
  • the amniotic membrane can be either wet or dry during the reinforcement process.
  • step (c) Immediately after placing the collagen sheet on human fibroblasts, seeding and culturing of biological cells (step (c)) can be performed, but preferably human fibroblasts are inoculated before seeding the biological cells. Incubate for a predetermined time (step (b) ').
  • step (b) ′ is effective for producing a high-quality biological tissue sheet.
  • the implementation of this step promotes the infiltration of human fibroblasts into the collagen sheet, and living body-derived cells can receive the supply of nutrient components with the strength of human fibroblasts from the initial stage of culture. .
  • the predetermined time here is, for example, 2 hours or more, preferably 1 day or more, more preferably 3 days or more, and even more preferably 5 days or more (f, 5 days, 6 days, 7 days).
  • living body-derived cells are prepared, and the living body-derived cells are seeded on a collagen sheet.
  • the cells derived from the living body use cells that are suitable for the purpose of the finally obtained living tissue sheet.
  • skin epidermal cells including stem cells and precursor cells
  • hair follicle epithelial cells including stem cells and precursor cells
  • corneal epithelial cells including stem cells and progenitor cells
  • mucosal epithelial cells for the purpose of regenerating mucosal epithelial tissue ( Their stem cells and progenitor cells) are preferably used.
  • mucosal epithelial cells include oral mucosal epithelial cells, intestinal mucosal epithelial cells, airway mucosal epithelial cells and the like.
  • the preparation method of living body-derived cells will be described taking skin epidermal cells, corneal epithelial cells, oral mucosal epithelial cells, intestinal mucosal epithelial cells and airway mucosal epithelial cells as examples. [0046] (Skin epidermal cells)
  • Corneal epithelial cells can be obtained from corneal limbal tissue force.
  • endothelium cells such as corneal limbal tissue force are detached and removed, and the conjunctiva is excised to produce a single cell suspension. This is stored in a nitrogen tank and then rapidly thawed at 37 ° C to prepare the corneal epithelial cell suspension.
  • Subculture if necessary. Moreover, you may use for subculture without cryopreserving.
  • EpiLife TM (Cascade), which is a serum-free medium, MCDB153 medium (Nissui Pharmaceutical Co., Ltd.), media prepared by modifying the amino acid composition of these media, etc. should be used. Can do.
  • Oral mucosal epithelial cells include cells present in the root of the tooth (inner oral mucosal epithelial cells), lip cells, palate cells, buttocks cells, and the like. Of these, the intraoral mucosal epithelial cells are particularly preferred because of their high proliferative ability and low antigenicity. Oral mucosal epithelial cells can be collected by excising the area where the target cells are present with a scalpel or by cleaving. In the oral marginal mucosal epithelial cells, the oral mucosal epithelium adhering to the tooth extraction can be separated from the enamel cement transition and collected. In order to remove impurities such as connective tissue, treatment with enzymes such as dispase or trypsin or filter treatment is preferred!
  • Intestinal mucosal epithelial cells are collected from colonoscopic intestinal epithelial biopsy tissue or open surgery Sometimes collected in the usual way.
  • epidermal cells can be excised from the tissue by lazer capture microdissection.
  • the technique of the present invention is also applied to a biological tissue sheet produced using all human digestive tract epithelial cells of the esophagus, stomach, duodenum, small intestine, and large intestine.
  • human gastrointestinal epithelium is damaged by ulcers or inflammation, bone marrow-derived cells play a rescue role in response to emergency situations, and the epithelium is repaired.
  • Gastrointestinal epithelial cells though some, are made by bone marrow.
  • the significance of the present invention can be regarded as equivalent to that using corneal epithelial cells.
  • the number of epithelial cells made from bone marrow which is usually only about a few thousand, increases from 50 times to 100 times in the process of healing ulcers (wounds) inside the gastrointestinal tract due to gastric ulcer, colitis, etc. It has been found that 1 in 10 gastrointestinal epithelial cells are derived from the bone marrow.
  • Gastrointestinal mucosal epithelial cell-derived tissue tissue prepared here is used for intractable ulcers and inflammation of enteric diseases such as severe intestinal infections, ulcerative colitis, Crohn's disease, Behcet's disease, etc. In the sense of promoting the regeneration of the intestinal epithelium, it is considered to be extremely meaningful. Expected to be useful for intestinal allergy
  • Airway mucosal epithelial cells are easily obtained from biopsy tissue of the airway mucosa, and in the same way as described above, treatment with an enzyme such as dispase trypsin or filtering is performed to remove impurities such as connective tissue. Is preferred. Airway mucosal epithelial cells play an important role in the pathogenesis of various infectious diseases through the biosynthesis and release of j8 defensin. The role of airway mucosal epithelium is high in asthma and allergic diseases! Providing a biological tissue sheet produced from the airway mucosal epithelial cells according to the present invention to the airway mucosa that has undergone tissue damage goes beyond the emergency response and leads to the provision of an artificial airway. In particular, the immunosuppressive action of the sheet prepared on the amniotic membrane is beneficial.
  • oral mucosal epithelial cells and intestinal mucosal epithelial cells are preferably treated with an enzyme such as dispase trypsin or filtered to remove impurities such as connective tissue after collection of the tissue.
  • an enzyme such as dispase trypsin or filtered to remove impurities such as connective tissue after collection of the tissue.
  • the living body-derived cells also have a person (recipient) ability to receive transplantation of the living tissue sheet.
  • the donor of the living cell and the recipient of the living transplant sheet are the same A person is preferred.
  • the prepared biological cells are seeded on a collagen sheet and then subjected to culture (step (d)).
  • Biological cells such as cell density of about 1 X 10 3 cells ZCM 2 or more, preferably rather about 1 X 10 3 cells / cm 2 ⁇ about 1 X 10 7 cells / cm 2, more preferably about 1 X 10 4 pieces / cm 2 to about 1 ⁇ 10 6 pieces Zcm 2 is seeded on the amniotic membrane.
  • hybridization the formation of a cell layer by two or more types of cells.
  • one cell type used when constructing a hybrid cell layer is defined as a first cell, and a cell type different from this is defined as a second cell.
  • the types of cells used in the construction of the hybridized cell layer will be described in detail below, taking as an example the case where the biological tissue sheet of the present invention is prepared for corneal epithelial reconstruction.
  • oral mucosal epithelial cells, conjunctival epithelial cells, nasal mucosal epithelial cells, other mucosal epithelial cells, or any one of these mucosal epithelia is used as one of the cell types (first cells) used to form the cell layer.
  • An undifferentiated cell that can be constructed is preferably used.
  • autologous cells are used for the first cell.
  • self refers to a subject to whom the biological tissue sheet of the present invention is applied, that is, a person (recipient) who receives a transplant. On the other hand, those other than “self” are called “others”.
  • corneal epithelial cells, conjunctival epithelial cells, or amniotic epithelial cells are preferably used as the cell type (second cell) used for forming the cell layer together with the first cells.
  • These cells are collected from the living tissue in which they are present. Specifically, for example, a part of the tissue in which the target cells are present is collected with a scalpel, etc., and then processed into a cell suspension (suspension) after removal of connective tissue, separation of cells, etc. To do. Two or more different types of cells may be used as the first cell. Similarly, two or more different types of cells may be used for the second cell.
  • stem cells have been suggested in the oral mucosal epithelium suitable as a collection source for the first cells, and it is considered that differentiation induction into cells forming an epithelial cell layer is easy.
  • using oral mucosal epithelial cells is easy to collect, can collect a large amount of cells, Has advantages such as the ability to prepare transplanted material using its own cells even when treating patients with binocular disease.
  • the advantage that the transplant material derived from one's own cells can be applied to patients who cannot collect corneal epithelial cells is expected to greatly eliminate the clinically important rejection problem.
  • Oral mucosal epithelial cells include cells present in the root of the tooth (inner oral mucosal epithelial cells), lip cells, palate cells, buttocks cells, and the like. Of these, the intraoral mucosal epithelial cells are particularly preferred because of their high proliferative ability and low antigenicity. Oral mucosal epithelial cells can be collected by excising the area where the target cells are present with a scalpel or by cleaving. In the oral marginal mucosal epithelial cells, the oral mucosal epithelium adhering to the tooth extraction can be separated from the enamel cement transition and collected. In order to remove impurities such as connective tissue, treatment with enzymes such as dispase or trypsin or filter treatment is preferred!
  • Oral mucosal epithelial cells collected from the oral cavity other than the patient to be transplanted with the sheet-like composition prepared according to the present invention can also be used, but considering immune rejection, oral mucosal epithelial cells from the patient's own oral cavity Is preferably collected and subjected to culture.
  • the oral mucosa has a high proliferative capacity, and usually wounds are healed by taking antibiotics for a few days after surgery, disinfecting with isodine, and so on.
  • the corneal epithelial cells of another person can be preferably used as the second cells.
  • Such corneal epithelial cells can be obtained from, for example, an infectious disease-free donor eyeball from an eye bank (Northwest Lions eye bank, etc.).
  • Cells usable as the second cell are not limited to corneal epithelial cells, and conjunctival epithelial cells, amniotic epithelial cells, and the like may be used.
  • a corneal epithelial cell which is a cell constituting the corneal epithelium in a living body, or a conjunctival epithelial cell existing in the vicinity thereof is employed, a sheet-like composition that better reproduces the characteristics of the corneal epithelium can be constructed. It is conceivable that.
  • a corneal epithelial cell was used as the second cell, a cell layer similar to the corneal epithelium could be constructed. This fact supports the above-mentioned expectation and confirms that corneal epithelial cells are particularly suitable as the second cells.
  • amniotic epithelial cells are used as the second cells, it is possible to form a cell layer that well reproduces the characteristics required for the cornea. It has been certified. This fact indicates that amniotic epithelial cells can be suitably used as the second cells.
  • the ability to use own cells as the second cells If other cells are used, the cells can be obtained more easily. For example, even when a sheet-like composition is prepared for treatment of a binocular patient, corneal epithelial cells as second cells can be obtained.
  • first cells and the second cells (hereinafter collectively referred to as "first cells etc.") prepared respectively are seeded on the amniotic membrane and subjected to culture.
  • first and second cells prepared in the form of a cell suspension are dropped onto the amniotic membrane and cultured.
  • the seeding of the first cell and the seeding of the second cell are performed at the same time (the term "simultaneous” here is literally the same time as well as placing a substantial time interval after one seeding. If the other cells are seeded at different timings, for example, the second cells are seeded after several minutes to several hours after the seeding of the first cells. Good. By shifting the seeding time in this way, for example, a region rich in cells derived from the first cell is localized and a cell layer is constructed, so that a homogeneous cell layer can be constructed. It is possible.
  • the ratio of the first cells and the like to be seeded is not particularly limited, but typically, approximately the same number of first cells and second cells are seeded.
  • the number of the first cells the number of the second cells S3: 7, 5: 5
  • Comparison of the cases of 7: 3 showed that there was no clear difference between them in terms of cell proliferation and stratification (data not shown).
  • living body-derived cells are cultured and grown in the absence of heterologous animal cells.
  • “in the absence of heterologous animal cells” means that animal cells that are heterologous to the living body-derived cells are not used as a condition for culturing the living body-derived cells.
  • human cells for example, human epidermal keratinocytes or human corneal epithelial cells
  • cells of animal species other than humans, such as mice and rats are present in the culture medium (coexisting) This is a condition that you do not want.
  • Culture of cells derived from living organisms can be performed by a conventional method.
  • the medium used for culturing living body-derived cells is not particularly limited as long as the cells can be grown.
  • M CDB153 medium Nisui Pharmaceutical Co., Ltd.
  • EpiLife TM Cascade
  • medium prepared by modifying the amino acid composition of these mediums DMEM (D A medium in which HSM medium and DMEM medium are mixed at a predetermined ratio, such as a medium in which ulbecco's modified Eagle's medium) and Ham's F12 medium are mixed at a predetermined ratio, can be used.
  • serum added to the medium human serum, fetal bovine serum, sheep serum, and the like can be used.
  • Human fibroblasts may be cultured using a medium supplemented with growth factors and antibiotics. By using growth factors and antibiotics, cell proliferation rate and survival rate can be improved and contamination can be prevented.
  • Biological cells may be cultured using a medium that is serum-free and does not contain a protein derived from a different animal. That is, a serum-free culture method may be employed as the culture method in the present invention. In such an embodiment, problems such as immune rejection due to contamination of serum-derived components can be avoided.
  • step (d) living body-derived cells grow on the collagen sheet.
  • step (e) a step in which the surface layer of the cell layer is brought into contact with air is performed. This step is also referred to as air lifting in this specification. This step (e) is performed for the differentiation of the cells forming the cell layer and the induction of the barrier function.
  • the surface of the culture solution is lowered by temporarily removing a part of the culture solution using a dropper, pipette, etc., thereby exposing the outermost layer of the cell layer to the outside of the culture solution. It can be carried out. Alternatively, the cell layer can be lifted together with the amniotic membrane, and the outermost layer can be temporarily exposed from the culture medium surface. Furthermore, air may be sent into the culture solution using a tube or the like, and air may be brought into contact with the uppermost layer of the cell layer. From the viewpoint of ease of operation, it is preferable to carry out the method by lowering the surface of the culture solution and exposing the outermost layer of the cell layer.
  • the time for performing this step (e), that is, the time for bringing the outermost layer of the cell layer into contact with air is a force that varies depending on the type of cell layer, the state of the cell, the culture conditions, etc.
  • it is preferably 5 days to 2 weeks, more preferably about 1 week.
  • it is preferably 2 days to 1 week, more preferably 2 days to 4 days.
  • a sheet-like construct obtained by culturing an amniotic membrane (first amniotic membrane) is adhered to one side of another amniotic membrane (second amniotic membrane), and a part of the first amniotic membrane is covered with the other one.
  • a structure having a cell layer covering the second amniotic membrane is transplanted into the epidermal defect part, and (2) epidermal keratinocytes cultured on the amniotic membrane placed on human fibroblasts are collected together with the amniotic membrane.
  • an excellent method for reconstructing the epidermis was to transplant it onto another amniotic membrane that had previously been transplanted into the skin defect.
  • the cultured epidermis is formed on the amniotic membrane, after transplantation, the cells that make up the cultured epidermis are promoted to proliferate and migrate to the surrounding area, and as a result, the cultured epidermis can rapidly expand. A high therapeutic effect can be obtained. Therefore, it is expected that an excellent therapeutic method can be established even for skin defects extending to a wide range of subcutaneous tissues by combining artificial dermal transplantation with the above transplantation technique.
  • step (f) a step of collecting the living body-derived cells together with the amniotic membrane as the collagen sheet; A step of culturing and proliferating the living body-derived cell after the living body-derived cell and the amniotic membrane are placed on another amniotic membrane (second amniotic membrane) with the amnion side down is further performed.
  • step (D and step (g) another amniotic membrane (second amniotic membrane) is adhered to one side of the amniotic membrane, and the amniotic membrane is partly covered and the other part is the second amniotic membrane.
  • a construct having a cell layer covering the amniotic membrane is obtained, wherein the entire surface of the second amniotic membrane is covered with the cell layer by appropriately adjusting the size of the second amniotic membrane, culture conditions, etc. And, a part of the surface of the second amniotic membrane is covered with a cell layer, so that one can obtain!
  • step (£) the cells derived from the living body after the culture and the amniotic membrane used as the culture substrate are collected.
  • the proliferating living cells and amniotic membrane can be recovered by peeling off the amniotic membrane after culturing.
  • step (g) the collected biological cells and the amniotic membrane are placed on another amniotic membrane, and then the biological cells are cultured again.
  • two-stage culture step (d) and step) is performed.
  • step (g) first, a construct comprising the collected biological cells and amniotic membrane (hereinafter referred to as “cell-amniotic membrane construct”) is placed on a separately prepared amniotic membrane (second amniotic membrane) with the amnion side down. Placed. Multiple cell-amniotic constructs can also be placed on the second amniotic membrane. For example, the cell-amniotic construct recovered after culturing in step (d) can be duplicated by cutting. Several cell-amniotic constructs can be obtained. Alternatively, it is possible to prepare a plurality of cell-amniotic constructs by preparing a plurality of culture systems independent of each other and carrying out step (d) in parallel.
  • the cell-amniotic constructs When a plurality of cell-amniotic constructs are placed on the second amniotic membrane, it is preferable to arrange the cell-amniotic constructs so that they are uniformly dispersed, that is, the intervals are constant. In subsequent cultures (and after transplantation into the living body), when the cells proliferate and the cell layer extends to the surroundings, the cell layer is quickly and efficiently removed from the area where the initial cell layer is not formed in the second amniotic membrane. It is because it can coat
  • the cell layer together with the second amniotic membrane can be transplanted into the tissue defect part of the living body. Formation of the layer is promoted and a high therapeutic effect is obtained.
  • the above method is particularly suitable for producing a cultured skin sheet (or a cultured skin sheet). If it is necessary to keratinize the surface layer of the cell layer, use the same method as above before step (1), between step (1) and step (g), or after step (g). Perform air lifting (step (e))
  • the culture in step (g) can be performed under the same conditions as the culture conditions in step (d). That is, it is preferable to use a medium that is serum-free and does not contain a protein derived from a heterologous animal as a medium that is preferably cultured in the absence of the heterologous animal cell. When using a medium containing serum, it is preferable to use autologous serum, the ability to use serum derived from the same species (human-derived serum when culturing human biological cells). Similarly to step (d), in step (g), the culture conditions may be changed during the culture step for the purpose of good growth of the cells derived from living organisms.
  • the biological tissue sheet of the present invention is used for regeneration (reconstruction) of skin epidermis, hair follicle epithelium, corneal epithelium, oral mucosal epithelium, intestinal mucosal epithelium, and airway mucosal epithelium.
  • the living tissue sheet of the present invention can be directly transplanted into a tissue defect part of a living body.
  • "Nao The “grafting” means transplantation without substantially interposing another substance between the tissue defect and the biological tissue sheet.
  • transplant the living tissue sheet of the present invention (except for those using the second amniotic membrane in the production process) into the tissue defect part of the living body so that other substances are interposed between them. You can also.
  • a biological tissue sheet can be transplanted into a tissue defect through an amniotic membrane (second amniotic membrane) different from the collagen sheet used as a culture substrate.
  • a biological tissue sheet prepared in advance can be transplanted onto the amniotic membrane.
  • the presence of amniotic membrane as a base is expected to allow the cells contained in the biological tissue sheet to proliferate efficiently and migrate well to the surroundings. That is, rapid extension of the cell layer constituting the biological tissue sheet can be expected, and a high therapeutic effect can be obtained.
  • the external defect is protected by covering the tissue defect with amniotic membrane. This also contributes to the improvement of the therapeutic effect.
  • amniotic membrane was collected at the cesarean section in the operating room. The operation was careful of cleanliness, and a special gown was worn after hand washing according to the surgical operation. Before delivery, a clean bat for collecting amnion and physiological saline for washing were prepared. After delivery, the placenta tissue was transferred to a vat and the amnion tissue was manually detached from the placenta. The adhesion between the amniotic membrane and the placenta was strong! The part was excised with scissors.
  • the amniotic treatment was performed in the order of (1) washing and chorionic membrane removal, (2) trimming, and (3) storage. In all processes, sterilize all containers and equipment that should be used in a clean fume hood and sterilize disposable dishes (dish, etc.). (Sportable) type was used. Remove blood components adhering to the collected amniotic membrane while rinsing with physiological saline, then rinsing with a sufficient amount of physiological saline, with the chorion facing upward, and visually form a pale white to white membrane. The observed chorion was detached. After this, the area near the placenta, which was uneven and opaque by hand touch and visual observation, was cut and removed with a scalpel.
  • amniotic membrane was divided into sizes of about 4 ⁇ 4 cm using a scalpel. After division, amniotic membranes in good condition were selected based on shape and thickness. Subsequently, the selected amnion was washed a total of 2 times with 5 g / mL gentamicin-added phosphate buffer (PBS).
  • PBS gentamicin-added phosphate buffer
  • amniotic membrane was washed twice with a sufficient amount of PBS, and the epithelium was manually cleaved (removed) using a cell scraper (Nunc USA) under a stereomicroscope.
  • the amniotic membrane with epithelial epithelium was placed in a 2 mL sterile cryotube supplemented with 1 mL of amniotic membrane preservation solution and stored at ⁇ 80 ° C. in an ultra-low temperature freezer until use.
  • optical and electron microscopic operations scanning electron microscope
  • Adipose tissue and dermis were removed as much as possible with scissors and washed several times with Dulbecco's phosphate buffer (PBS). Subsequently, it was sterilized by immersion in 70% ethanol for 1 minute. After washing with PBS, cut into strips 3mm wide and 10mm long and soaked in Dispase Solution (Dispase II, Godo Shusei, 250 units / ml Dulbecco's Modified MEM Medium; DMEM) at 4 ° C (18-24 hours). The next day, the epidermis was peeled from the dermis using tweezers. The peeled dermis is subjected to fibroblast culture (3. below).
  • the peeled epidermis is washed with DMEM, then washed with PB S, and then immersed in a 0.25% trypsin solution at 37 ° C for 10 minutes. A trypsin treatment was performed. The treated epidermis was transferred to a plastic petri dish containing a trypsin neutralizing solution, and then the epidermis pieces were loosened with tweezers. The resulting cell suspension was transferred to a 50 ml sterile tube. PBS was added to prepare the epidermal keratinocyte suspension. After counting the number of cells, the cells were centrifuged at lOOOOrpm for 5 minutes to precipitate the cells.
  • the cells were suspended in MCDB153 medium, which is a serum-free medium.
  • the cell suspension thus obtained was seeded at a rate of 2 to 3 ⁇ 10 6 cells / ⁇ culture medium per 100 mm collagen coated petri dish (Asahi Techno Glass, type I collagen coated dish; 4010-010).
  • the culture solution was changed the next day, and thereafter the culture solution was changed every other day. Subculture was performed when the cell density reached about 70-80%.
  • the remaining cells were collected using PBS. 10 centrifuge tubes The cells were centrifuged at 00 rpm for 5 minutes to precipitate the cells, and the supernatant was removed by aspiration. DMEM medium containing 10% fetal bovine serum was added to the centrifuge tube to suspend the cells. The fibroblast suspension thus obtained was seeded in a cell culture dish. Subculture was performed when the cell density reached 90-100%. The cells were stored frozen as appropriate. The cryopreservation solution was stored in liquid nitrogen using 10% glycerol, 20% FCS, and 70% DMEM.
  • the fibroblasts cultured in (1) were taken out and confirmed to be confluent with a phase-contrast microscope, and then loaded into a safety cabinet. Remove medium in 100 mm dish (or 60 mm dish) containing fibroblasts, wash with PBS (-), add 0.05% trypsin-EDTA, 37 ° C, 5% CO Let sit for 2 minutes under. Phase contrast after 2 minutes
  • trypsin reaction was stopped by adding DMEM supplemented with 10% FBS.
  • the cell suspension was collected in a 15 mL tube.
  • the supernatant was removed by centrifuging at 1000 rpm for 5 minutes at room temperature in a desktop multi-centrifuge. During centrifugation, 5 mL of DMEM supplemented with 10% FBS was injected into a 100 mm dish, and then a culture insert (manufactured by Coaster) was placed.
  • a part of the cell suspension prepared by suspending the cell precipitate after centrifugation in DMEM supplemented with 10% FBS was mixed with an equal amount of 0.4% trypan blue, and the number of cells and the cell viability were measured with a hemocytometer. Based on the measurement results, the cell suspension was diluted with DMEM supplemented with 10% FBS to 2.1xl0 5 cells / mL. 10 mL of diluted cell suspension was added to the culture insert. In order to adhere the cells, dish (37 ° C, 5% CO in a CO incubator)
  • the amniotic membrane is treated as follows.
  • the amniotic membrane (freeze-stored) prepared in 1 above was thawed at room temperature and transferred to a 100 mm diameter Petri dish. Subsequently, the amniotic membrane was washed in two 100 mm diameter Petri dishes containing PBS (-) containing 5 g / mL gentamicin, and then immersed in a 60 mm diameter Petri dish containing 10% FBS-added DMEM.
  • a 0-ring was placed on the amniotic membrane using an insulative scissors to prevent the amniotic membrane from floating. Place the culture insert with amniotic membrane attached on a 100mm dish according to the above procedure, then inject 1 mL of 10% FBS-added DMEM into the culture insert, and then in a CO incubator at 37 ° C and 5% CO. Left to stand.
  • human epidermal keratinocytes were seeded on the amnion.
  • the human epidermal keratinocytes prepared in 2. were peeled off using trypsin 'EDTA and collected.
  • An epidermis keratinocyte suspension adjusted to a concentration of 2 million cells / 0.25 ml by centrifugation was obtained.
  • the dish with the culture insert seeded with human fibroblasts and amnion was removed from the CO incubator and loaded into a safety cabinet.
  • the culture medium in one insert was removed, and the outside of the culture insert was removed leaving about 5 mL of culture medium. After 0.5 ml of epidermal keratinocyte suspension was seeded on the amniotic membrane in the culture insert, it was transferred into a CO incubator. 1.5 so that epidermal keratinocytes adhere to the amniotic membrane
  • the submerged culture solution was prepared as follows.
  • Serum-free medium for keratinocytes 3 doses plus 1 dose of DMEM Medium containing 0.3% tuss fetal serum
  • Air-lifting was performed about 2 days after seeding of epidermal keratinocytes.
  • the culture medium inside and outside the culture insert was carefully removed, and 1.6 mL of the culture medium for stratification was added outside the culture insert.
  • the culture medium was changed twice a day in the morning and evening.
  • the cultured skin sheet was completed after 7 days of air exposure.
  • the culture solution for stratification was prepared as follows.
  • Serum-free medium for keratinocytes 1 dose of DMEM plus 1% culture medium containing fetus serum
  • the cultured skin sheet constructed by the above culture method was transplanted with the amnion side as the contact surface to the skin defect formed on the back of nude mice.
  • a part of the tissue at the transplant site was excised to prepare a specimen and subjected to HE staining.
  • frozen tissue sections were prepared and subjected to immunohistochemical staining. Immunohistochemical staining was performed using Chile's Histofine SAB-AP kit and Eufuxin was used as a substrate.
  • the antibodies used for immunohistochemical staining are as follows.
  • E-cadherin HECD-1, Tak ara
  • keratin 10 LHP1, NeoMarkers
  • j8 4 integrin 3E1, Chemicon
  • ⁇ 2 integrin MAB1950, Chemicon
  • keratin 14 LL002, NeoMarkers
  • laminin 5 G1, Sera-Lab
  • type IV collagen 2311C3, Chemicon
  • type VII collagen LH7.2, NeoMar kers
  • polyclonal antibody desmoglein 3 ( 5 G11, Zymed).
  • Fig. 3 shows the HE-stained image.
  • the magnification is increased in the order of upper left, upper right, lower left, and lower right.
  • a skin layer of about 10 m is formed.
  • the grafts were well engrafted and the morphology of the epidermis was close to that of normal skin. That is, it consisted of a more compact stratum corneum than the upper layer, 1 to 2 granular layers, 5 to 8 spiny layers, and 1 basal layer.
  • Strongly enlarged findings showed dense adhesion at the epidermis / dermis junction, and many images of fibroblasts entering the amnion.
  • many luminal structures are seen in the dermis directly under the amniotic membrane, resulting in the formation of capillaries. It became clear that it was done actively.
  • laminin 5 type IV collagen, and type VII collagen, which are the main constituents of the basement membrane, are expressed in the epidermis / dermis junction, and the pattern is normal skin. And almost the same.
  • E-cadherin a major component of epidermal cell junction, is expressed between cells in all layers, and oc 2 intedarin and j8 4 integrin are expressed between cells, mainly in the basal layer, and are distributed almost the same as normal skin.
  • Desmoglein 3 a constituent protein of desmosome, was expressed between cells from the basal layer to the parabasal layer, and the expression pattern was similar to that of normal skin.
  • Keratin 10 was expressed from the parabasal layer to the upper spiny layer, and was expressed in the same manner as in normal skin.
  • Keratin 14 was expressed in the basal layer and the parabasal layer, and the expression pattern was slightly different from the expression of only the basal layer in normal skin (Figs. 4 and 5).
  • the cultured skin sheet produced by the above method has properties similar to normal epidermis and functions effectively as a skin reconstruction transplant material.
  • the cultured skin sheet that is finally constructed after seeding the epidermis keratinocytes, that is, the time until the epidermis keratinocytes are seeded after the amnion is placed (attached) on the monolayer fibroblasts
  • the effect on the quality of food was examined.
  • the outline of the experimental method is shown in the upper part of Fig. 6.
  • condition 1 condition for seeding epidermis keratinocytes after placing on the amniotic membrane, the experimental procedure on the upper left side of Fig. 6
  • the epidermal keratinocytes were removed 5 days after placing the amniotic membrane on fibroblasts. Sowing.
  • condition 2 the condition in which epidermal keratinocytes are seeded without placing time after placing the amniotic membrane, the experimental procedure on the upper right side of FIG. 6
  • the epidermal keratinocytes immediately after placing the amniotic membrane on the fibroblasts. Sowing.
  • amniotic membrane should be placed 4 hours after seeding of fibroblasts in condition 1, and amniotic membrane should be placed 5 days after seeding of fibroblasts in condition 2. I rubbed.
  • the constructed cultured skin sheets were each stained with HE and evaluated histologically.
  • Condition 1 The HE-stained image of the cultured skin sheet constructed in Fig. 6 is shown in the lower left of Fig. 6, and the HE-stained image of the cultured skin sheet constructed in Condition 2 is shown in the lower right of the figure.
  • keratinocytes are more regularly aligned in the epidermal layer formed on the amniotic membrane than in the cultured skin sheet constructed in condition 2.
  • the skin layer of the cultured skin sheet constructed under Condition 1 is thicker, and a gradual layer structure is clearly recognized. Furthermore, the flatness and denseness of the stratum corneum located at the uppermost part of the skin layer are also good.
  • the cultured skin sheet constructed under condition 1 shows infiltration of many fibroblasts. Therefore, in the culture method under Condition 1, many fibroblasts infiltrate into the amniotic membrane before the seeding of the amniotic membrane placement force epidermal keratinocytes, and this causes growth of the epidermal keratinocytes. It is presumed that a high-quality skin layer was formed as a result of preparing a suitable environment.
  • the constructed cultured skin sheets were each stained with HE and evaluated histologically.
  • the HE-stained image of the cultured skin sheet constructed in Condition 1 is shown in the lower left of Fig. 7, and the HE-stained image of the cultured skin sheet constructed in Condition 2 is shown in the lower right of the figure.
  • the cultured skin sheet constructed under condition 2 has a thicker epithelial layer and a clear stratum corneum than the cultured skin sheet constructed under condition 1. Shikaso also has good flatness and denseness of the stratum corneum.
  • the amniotic membrane when focusing on the amniotic membrane and fibroblasts used as the culture substrate, the amniotic membrane between conditions 1 and 2 Although the number of fibroblasts that infiltrate into the cells does not differ greatly, a fibroblast layer that uniformly covers the bottom of the amniotic membrane is observed in the cultured skin sheet constructed under condition 2. From this, under condition 2, after fibroblasts are seeded, a sufficient amount of time is applied to place the amniotic membrane for good adhesion of fibroblasts to the surface of the culture insert and fibroblasts.
  • amniotic membrane from which the epithelium was removed was prepared in the same manner as in the case of producing a cultured skin sheet
  • the cornea was purchased from Northwest Lions Eye Bank (Seattle, USA) with a grade equivalent to that for transplantation.
  • the central part of the cornea was punched and removed with a 7.0 mm trepan blade, the conjunctiva was removed with a scissors under the stereomicroscope, the sclera was removed with a scalpel, and the substantial part was removed with a scissors.
  • the corneal epithelial tissue is washed with PBS (-), then immersed in 1.2 U / mL Dispase solution (Roche, Dispasell, 2.4 U / mL), in a CO incubator under 5% CO condition at 37 ° C for 1 hour.
  • the corneal epithelial tissue was immersed in 0.02% EDTA-added PBS (-) and PBS (-) in this order for 2 minutes at room temperature.
  • the epithelial cells are detached using a pestle and the cell mass A corneal epithelial cell suspension containing a large amount of was prepared.
  • the corneal epithelial cell suspension was divided into two aliquots of 1.2 mL, and 0.3 mL of 0.25% trypsin EDTA (Invitrogen) was added to each suspension and mixed.
  • the corneal epithelial cell suspension prepared in this manner was transferred to a 15 mL centrifuge tube. After suspension, a part of the cell suspension was mixed with an equal volume of 0.4% trypan blue, and the cell viability was measured with a hemocytometer.
  • the 15 mL centrifuge tube containing the cell suspension was centrifuged at 1000 rpm for 5 minutes at room temperature using a desktop multi-centrifuge, and the supernatant was removed.
  • the HSM medium was added to the tube after centrifugation so that the total volume was 1.0 mL, and the cells were suspended. CO 2 incubator at 37 ° C, 5% CO.
  • Static culture was performed in one.
  • the cell growth rate and cell morphology of the cells were observed using a phase contrast microscope under a magnification of 100 times. Once grown to approximately 70% subconfluent, the cells were passaged as follows. The subculture was repeated until the number of cells necessary for production of the cultured corneal epithelial sheet was obtained.
  • the HSM culture solution was placed in a centrifuge tube to make 1.0 mL, and the cells were suspended.
  • Human fibroblasts were prepared in the same manner as in the production of cultured skin sheets.
  • Human fibroblasts were seeded on the culture insert and amnion was placed in the same manner as in the production of the cultured skin sheet. However, a 6-well plate was used in place of the 100 mm dish, and a culture insert (Coaster Co., Ltd.) suitable for the 6-well plate was used.
  • Corneal epithelial cells were seeded on the amniotic membrane 5 days after the amnion sticking operation. First, the corneal epithelial cells prepared in 2 were observed with a phase contrast microscope, and it was confirmed that they were about 70-80% subconfluent. The culture solution was removed, washed with PBS ( ⁇ ), added with 2 mL of 0.05% trypsin-EDTA, and allowed to stand at 37 ° C., 5% CO for 5 minutes. Then trypsin inhibitor
  • the 15 mL centrifuge tube containing the cell suspension was centrifuged at 1000 rpm for 5 minutes at room temperature using a desktop multi-centrifuge. After centrifugation, the supernatant was removed, and the submerged A culture solution was added to the centrifuge tube so that the cell count was 1 ⁇ 10 3 cells / l based on the cell count results, and the cells were suspended.
  • the 6-well plate on which the culture insert on which human fibroblasts were seeded and amnion was affixed was taken out of the CO incubator and carried into a safety cabinet.
  • the culture medium inside and outside the culture insert was removed, and about 1 mL of submerged A culture medium was added outside the culture insert. Inoculate the corneal epithelial cell suspension prepared at 1 X 10 3 cells / l on the amniotic membrane in the culture insert, and use the submerged A medium so that the volume of the solution in the culture insert is 1 mL. I made a mess up.
  • a 6-well plate on which a cell-seeded cell insert is placed is loaded into a CO incubator, 37 ° C, 5% Static culture was performed under CO conditions.
  • the inner and bottom surfaces of the culture insert were washed with PBS (-) containing 5 g / mL gentamicin, and the culture insert was placed on a silicone sheet in a 100 mm diameter Petri dish with the culture insert mark on top.
  • the insert was placed and the sheet was punched out with an 18 mm trepan. It was placed on a 9mm graph paper (OHP) with a silicone mat, taking care not to lose power in the top, bottom, left and right.
  • the top, bottom, left, and right edges were on the grid line, and the sheet was cut with a force razor along the line passing through the center, and divided into four equal parts. Two sheets on the diagonal of this equally divided sheet were embedded using OCT compound.
  • the corneal epithelial cell layer was peeled off from the amniotic membrane in a sheet form, immersed in 2.5 mL of 0.05% trypsin-EDTA solution, and allowed to stand in a CO incubator under 5% CO conditions at 37 ° C for 5 minutes. So
  • the cell suspension suspended by pipetting and converted into a single cell was transferred to a 15 mL centrifuge tube.
  • the supernatant was removed by centrifugation at 1500 rpm for 5 minutes at room temperature in a table-top multi-centrifuge.
  • SHEM was placed in a centrifuge tube so that the total volume was 1.0 mL, and the cells were suspended.
  • a portion of the cell suspension was taken and mixed with an equal volume of 0.4% trypan blue, and the cell count and cell viability were measured with a hemocytometer.
  • the number of cells per cell and the survival rate of these sheets were 1.4 xlO 6 cells and 96.8%, respectively.
  • the cultured corneal epithelial sheet embedded in 7-2 above was sliced with a cryostat to prepare slide sections. This slide section was subjected to HE staining as described below. The following operations were performed at room temperature.
  • the slide sections were fixed with mild form for 5 minutes, and then washed with running water for about 10 minutes. After washing, the cells were stained with hematoxylin for 5 to 10 seconds and washed with running water for 5 to 10 minutes. Next, it was stained with eosin for 3 to 5 seconds and washed with running water for 5 to 15 minutes. After washing, dehydration was performed for several seconds in order of 70, 90, 95%, and absolute ethanol. After dehydration with absolute ethanol, it was immersed in xylene for 5 minutes and then immersed in fresh xylene for 30 minutes or more. After that, the mounting medium (Yanteran-Yu) was dropped, the cover glass was placed, the slide was sealed, and when the mounting medium was dry, the coating was applied around the cover glass. When the cure was dry, it was observed with an optical microscope.
  • the prepared cultured corneal epithelial sheet had an epithelial layer stratified into 4-6 layers with a thickness of about 50 m (Fig. 8).
  • a group of cells similar to basal cells having a comparative columnar shape existed on the basal side (amniotic membrane side) of this epithelial layer.
  • the outermost cell has a flat core that is flat, and unlike the skin, its surface is not keratinized. was confirmed. From the above, it was shown by optical microscope observation that an epithelial layer similar to normal cornea was formed on the amniotic membrane.
  • Immunostaining was performed to examine the immunohistological characteristics of the prepared cultured corneal epithelial sheet.
  • keratin-specific keratins 3 and 12 were examined.
  • the cultured corneal epithelial sheet embedded in 7-2 above was sliced with a cryostat to prepare a slide section.
  • the slide sections were subjected to immunostaining as described below. First, the slide sections were washed with PBS ( ⁇ ) and then blocked with 1% BSA to suppress nonspecific antibody reaction. Thereafter, an antibody against each keratin (primary antibody) was reacted at room temperature for 1 hour. After the reaction, it was washed with a blocking solution containing Triton X-100 for 15 minutes under the conditions of 3 times, and then a fluorescently labeled antibody (secondary antibody) was reacted at room temperature for 1 hour.
  • the antibodies used are as follows. Primary antibody: Keratin 3 (cytokeratin3 / 12, PROGEN ⁇ Cat.No.61807), Keratin 12 (Anti—Keratinl2, Transgenic Inc ⁇ Cat.No. KR074) Secondary antibody: Alexa488 anti mouse (Molecular probes ⁇ Cat.No. .A- 11029, used for keratin 3), Alexa488 anti rabbit (Molecular probes, Cat. No. A-11034, used for keratin 12)
  • the amnion from which the epithelium was removed prepared by the procedure described in 1. of Example 1, was immersed in a 10% (w / v) trehalose solution at 37 ° C. for 2 hours.
  • the trehalose solution was prepared by diluting trehalose (Toreno Life Co., Ltd., Life Plus, Life Sciences, Hayashibara) with distilled water.
  • the pH of the solution was kept in the range of 7-10.
  • the amniotic membrane was clamped with a pair of sterilized plastic frames and then fixed with clips. 80 ° C deep free per frame After confirming that the amniotic membrane was frozen, freeze drying (-110 ° C, about 1 hour) was performed using a vacuum freeze dryer (Yamato, NEOCO OL).
  • a cultured skin sheet is obtained in the same manner as in 2. to 6. of Example 1 except that the trehalose-treated lyophilized amniotic membrane obtained in 1. is used as the amniotic membrane used for the culture substrate.
  • a cultured corneal epithelial sheet is obtained in the same manner as in 2. to 6. of Example 2, except that the trehalose-treated lyophilized amniotic membrane obtained in 1. is used as the amniotic membrane used as the culture substrate.
  • the use of the biological tissue sheet provided by the present invention can be used for regeneration (reconstruction) of wide skin epidermis, corneal epithelium, oral mucosal epithelium, airway mucosal epithelium and intestinal mucosal epithelium. Among these, it can be suitably used for regeneration of the skin epidermis or corneal epithelium.
  • the biological tissue sheet of the present invention can be used for gene therapy.
  • gene therapy There are two types of gene therapy, in vivo and ex vivo.
  • the former is a method in which a gene is directly introduced into a living body, and the latter is a method in which a cell is taken out and the gene is introduced and then returned to the body.
  • an ex vivo method is immediately developed as long as a gene is introduced into cultured skin, cultured corneal epithelium, or cultured intestinal mucosal epithelial sheet.
  • the effectiveness of gene transfer into keratinocytes by various viral vectors has been shown, and in particular, when an adenovirus vector is used, it can be introduced into almost 100% of keratinocytes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L’invention divulgue une feuille de tissu biologique susceptible d’exercer un effet thérapeutique très favorable et très sûre en transplantation. Un procédé d’obtention d’une feuille de tissu biologique comprend les étapes : (a) obtention d’un fibroblaste humain ; (b) pose d’une feuille collagène sur le fibroblaste humain ensemencé dans une cuve de culture ; (c) préparation d’une cellule biologiquement dérivée et son ensemencement sur la feuille collagène et (d) culture de la cellule biologiquement dérivée en l’absence de cellule dérivée d’un autre animal pour la faire croître.
PCT/JP2006/317510 2005-09-07 2006-09-05 Feuille de tissu biologique et procédé de préparation WO2007029676A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-259019 2005-09-07
JP2005259019 2005-09-07

Publications (1)

Publication Number Publication Date
WO2007029676A1 true WO2007029676A1 (fr) 2007-03-15

Family

ID=37835796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/317510 WO2007029676A1 (fr) 2005-09-07 2006-09-05 Feuille de tissu biologique et procédé de préparation

Country Status (1)

Country Link
WO (1) WO2007029676A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014204711A (ja) * 2013-03-19 2014-10-30 国立大学法人 千葉大学 三次元培養皮膚モデルの製造方法およびその利用
JP2019536596A (ja) * 2016-11-02 2019-12-19 アクソジェン コーポレーション 羊膜組織グラフトとその調製方法及び使用方法
CN111888529A (zh) * 2020-07-20 2020-11-06 肖雁冰 基于人羊膜及羊膜间充质干细胞的仿生羊膜及方法和应用
WO2021039833A1 (fr) * 2019-08-29 2021-03-04 国立大学法人愛媛大学 Procédé de production de tissu cultivé, et préparation pour application externe

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506169A (ja) * 1990-04-24 1993-09-16 エイゼンバーグ，マーク 合成生体皮膚等価物
JP2001161353A (ja) * 1999-12-09 2001-06-19 Japan Ophthalmic Consultants:Kk 移植用細胞片及びその作成方法
JP2002320666A (ja) * 2000-09-26 2002-11-05 Sanyo Chem Ind Ltd 人工角膜の製造方法
WO2003043542A1 (fr) * 2001-11-19 2003-05-30 Amniotec Inc. Feuille du type epithelium corneen et procede de construction associe
JP2005013717A (ja) * 2003-06-06 2005-01-20 Nipro Corp 培養表皮及びその培養方法
JP2005348736A (ja) * 2004-06-11 2005-12-22 Bioland Ltd 細胞培養用膜の支持装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506169A (ja) * 1990-04-24 1993-09-16 エイゼンバーグ，マーク 合成生体皮膚等価物
JP2001161353A (ja) * 1999-12-09 2001-06-19 Japan Ophthalmic Consultants:Kk 移植用細胞片及びその作成方法
JP2002320666A (ja) * 2000-09-26 2002-11-05 Sanyo Chem Ind Ltd 人工角膜の製造方法
WO2003043542A1 (fr) * 2001-11-19 2003-05-30 Amniotec Inc. Feuille du type epithelium corneen et procede de construction associe
JP2005013717A (ja) * 2003-06-06 2005-01-20 Nipro Corp 培養表皮及びその培養方法
JP2005348736A (ja) * 2004-06-11 2005-12-22 Bioland Ltd 細胞培養用膜の支持装置

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014204711A (ja) * 2013-03-19 2014-10-30 国立大学法人 千葉大学 三次元培養皮膚モデルの製造方法およびその利用
JP2019536596A (ja) * 2016-11-02 2019-12-19 アクソジェン コーポレーション 羊膜組織グラフトとその調製方法及び使用方法
JP7171588B2 (ja) 2016-11-02 2022-11-15 アクソジェン コーポレーション 羊膜組織グラフトとその調製方法及び使用方法
US11577001B2 (en) 2016-11-02 2023-02-14 Axogen Corporation Amnion tissue grafts and methods of preparing and using same
WO2021039833A1 (fr) * 2019-08-29 2021-03-04 国立大学法人愛媛大学 Procédé de production de tissu cultivé, et préparation pour application externe
CN111888529A (zh) * 2020-07-20 2020-11-06 肖雁冰 基于人羊膜及羊膜间充质干细胞的仿生羊膜及方法和应用

Similar Documents

Publication Publication Date Title
WO2005087286A1 (fr) Feuille de tissu biologique, méthode de formation de celle-ci et méthode de transplantation utilisant la feuille
KR101313033B1 (ko) 시트형 조성물
Baiguera et al. Tissue engineered human tracheas for in vivo implantation
US6916655B2 (en) Cultured skin and method of manufacturing the same
RU2461622C2 (ru) Биоинженерный конструкт для имплантации ткани и способ изготовления названного биоинженерного конструкта (варианты)
RU2645473C2 (ru) Тканевые конструкции, полученные с помощью биоинженерии, и способы их получения и применения
WO2006075602A1 (fr) Composition en forme de feuille utilisant un amnios et procédé de préparation de celle-ci
WO2004078225A1 (fr) Materiau medical d'origine amniotique et son procede de preparation
JP4397082B2 (ja) 移植用細胞片及びその作成方法
WO2015105249A1 (fr) Composition de support biodégradable à base d'hydrogel-cellules souches mésenchymateuses ou non dégradable à base d'hydrogel-cellules souches mésenchymateuses pour une régénération de la peau ou une cicatrisation de plaie
RU2498808C2 (ru) Способ лечения состояния ротовой полости больного (варианты)
WO2003043542A1 (fr) Feuille du type epithelium corneen et procede de construction associe
WO2006003818A1 (fr) Surface épithéliale cornéenne et processus de production
WO2007043255A1 (fr) Feuillet endothélial cornéen cultivé et son procédé de production
Qi et al. Construction and characterization of human oral mucosa equivalent using hyper-dry amniotic membrane as a matrix
JPWO2005087285A1 (ja) 角膜上皮シート及びその作製方法、並びに同シートを用いる移植方法
WO2007029676A1 (fr) Feuille de tissu biologique et procédé de préparation
JP2009225675A (ja) 上皮系細胞シートの作製のための同種皮膚由来フィーダー細胞
ES2353990B1 (es) Elaboracion de tejidos artificiales mediante ingenieria tisular utilizando biomateriales de fibrina y agarosa.
WO2006090696A1 (fr) Procédé de fabrication d’un amnion dénué d’épithélium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06797416

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP